Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 621-624

  Takumi, Ochiai ^a   Nishimura, Kazuhiko ^a   Watanabe, Tomoo ^a   Kitajima, Masayuki ^a   Nakatani, Akinori ^a   Inou, Takashi ^a   Washio, Marie ^a   Sakuyama, Naoki ^a   Sato, Tsuyoshi ^a   Kishine, Kenji ^a   Ochi, Takanori ^a   Okubo, Satoshi ^a   Futagawa, Shunji ^a   Mashiko, Satomi ^a   Nagaoka, Isao ^b  

^a Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen gel droplet embedded drug sensitivity test; Colon cancer; Individualized chemotherapy; Leucovorin and fluorouracil plus irinotecan; Leucovorin and fluorouracil plus oxaliplatin

Indexed keywords

FIRTECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; COLLAGEN GEL DROPLET EMBEDDED DRUG SENSITIVITY TEST; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZATION; INFORMED CONSENT; MALE; PREOPERATIVE TREATMENT; TUMOR CELL;

EID: 84864703728     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.823     Document Type: Article

References (31)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
3. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and f luorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
4. Douillard JY, Cunningham D, Roth A D, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
5. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
6. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and f luoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 21: 3523-3529, 2008.
7. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, f luorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25: 1539-1544, 2007.
9. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
10. Maughan TS, Adams R, Smith CG, et al: Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-f luoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC). J Clin Oncol 28 (Suppl 5): abs. 3502, 2010.
11. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral f luoropy-rimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007.
12. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemo-therapy as initial treatment for metastatic colorectal cancer. N Eng J Med 360: 1408-1417, 2009.
13. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
14. Grothey A and Sargent D: Overall survival of patients with advanced colorectal cancer cor relates with availability of fluorouracil, irinotecan and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23: 9441-9442, 2005.
15. Ochiai T, Nishimura K, Watanabe T, et al: Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Exp Ther Med 1: 325-329, 2010.
16. Kobayashi H, Tanisaka K, Doi O, et al: An in vitro chemosensi- tivity test for solid tumors using collagen gel droplet embedded cultures. Int J Oncol 11: 449-455, 1997.
17. Kobayashi H, Higashiyama M, Minamigawa K, et al: Examination of in vitro chemosensitivity test using collagen droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 92: 203-210, 2001.
18. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019, 2011.
19. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
20. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxali- platin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
21. Koopman M, Venderbosch S, van Tinteren H, et al: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomized CAIRO study. Eur J Cancer 45: 1999-2006, 2009.
22. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH and Punt CJ: A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 45: 1935-1949, 2009.
23. Ochiai T, Nishimura K, Noguchi H, et al: Prognostic impact of orotate phosphoribosyl transferase among 5-f luorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118: 3084-3088, 2006.
24. Ochiai T, Nishimura K, Watanabe T, et al: Evaluation of the individual 50% inhibitory area under the concentration curve of 5-fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer. Mol Med Rep 2: 405-409, 2009.
25. Ochiai T, Nishimura K, Watanabe T, et al: Personalized adjuvant chemotherapy for colorectal cancer (CRC) based on an individual 50% inhibitory area under the concentration curve (AUC) using collagen gel droplet embedded culture-drug sensitivity test (CD-DST). J Clin Oncol 28 (Suppl 15): abs. 3582, 2010.
26. Braun MS, Richman SD, Quirke P, et al: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26: 2690-2698, 2008.
27. Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pha r macogenet Genomics 17: 497-504, 2007.
28. Ando Y, Saka H, Ando M, et a l: Poly mo r ph i sm s of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
29. Sai K, Sawada J and Minami H: Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1 *6 and *28. Yakugaku Zasshi 128: 575-584, 2008 (In Japanese).
30. Seymour MT, for the UK NCRI colorectal clinical studies group: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). J Clin Oncol 23 (Suppl 16): abs. 3518, 2005.
31. Köhne CH, Van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European organization for research and treatment of cancer gastrointestinal group study 40986. J Clin Oncol 23: 4856-4865, 2005.